( NASDAQOTH:MJNA ). While GW Pharmaceuticals currently holds the title of being the largest pot stock by a mile, Medical Marijuana, Inc. holds the distinction of being the first publicly listed marijuana stock. Unlike most marijuana stocks that tend to focus on developing a handful of products or a small portfolio of cannabinoid-based drugs, Medical Marijuana, Inc. is a holding company that’s invested in more than a half-dozen cannabidiol (CBD)-product companies for the pharmaceutical, nutraceutical, cosmeceutical, or industrial hemp industries. The company’s eight listed subsidiaries and investments include: HempMeds, which offers marketing and sales of CBD-based products in the U.S.; Kannaway, which specializes in hemp-based botanical products; KannaLife Sciences, which is a cannabinoid-based drug developer; Axim Biotechnologies, which is also a developer of cannabinoid-based medicines; MPS International, a security consultation service for the weed industry; Wellness Managed Services, which provides support services to the pot industry. The most obvious reason marijuana stock investors are Green Rush likely excited about a company like Medical Marijuana, Inc. is its portfolio diversity. Its complete ownership of HempMeds and investments in KannaLife Sciences and Axim Biotechnologies gives the company access to retail CBD product sales, as well as the opportunity to earn significant investment rewards if Axim’s and KannaLife’s cannabinoid-based products succeed in clinical trials.